Loading…

Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients

Background Neoadjuvant radiochemotherapy (RCT) is thought to result in a favorable oncological outcome in esophageal cancer patients. Unfortunately, it also implies that adjacent healthy tissue is preoperatively exposed to the potential damaging influence of RCT. Here, the impact of preoperative RCT...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2009-05, Vol.16 (5), p.1384-1389
Main Authors: Rieff, E. A., Hendriks, T., Rutten, H. J. T., Nieuwenhuijzen, G. A. P., Gosens, M. J. E. M., van den Brule, A. J. C., Nienhuijs, S. W., de Hingh, I. H. J. T.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103
cites cdi_FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103
container_end_page 1389
container_issue 5
container_start_page 1384
container_title Annals of surgical oncology
container_volume 16
creator Rieff, E. A.
Hendriks, T.
Rutten, H. J. T.
Nieuwenhuijzen, G. A. P.
Gosens, M. J. E. M.
van den Brule, A. J. C.
Nienhuijs, S. W.
de Hingh, I. H. J. T.
description Background Neoadjuvant radiochemotherapy (RCT) is thought to result in a favorable oncological outcome in esophageal cancer patients. Unfortunately, it also implies that adjacent healthy tissue is preoperatively exposed to the potential damaging influence of RCT. Here, the impact of preoperative RCT on matrix metalloproteinase (MMP) expression in healthy esophageal tissue aligned with the tumor at the time of surgery is examined. Patients and Methods 23 patients participating in a clinical trial were randomized to either the control ( n  = 12) or the neoadjuvant RCT group ( n  = 11). In the latter group, surgery was performed 5 weeks after the last course of RCT. Full-thickness biopsies were taken from healthy esophageal tissue at the proximal border of the resection specimen and more distally next to the tumor. MMP-2 and MMP-9 activity in the samples was assessed by quantitative gelatin zymography and immunohistochemistry. Results In the proximal segment, the activities of the MMP-9-dimer (135 kDa) and proMMP-9 (92 kDa) were significantly increased in the RCT group as compared with the control group: 28.5 versus 3.0 ( p  = 0.025) and 87.7 versus 13.0 ( p  = 0.015) arbitrary units for 135 kDa and 92 kDa, respectively. In the distal part, RCT resulted in a significant increase of proMMP-2 (72 kDa: 35.8 versus 17.8, p  = 0.005) and proMMP-9 (81.2 versus 23.3, p  = 0.03). Conclusion In esophageal cancer patients, neoadjuvant RCT results in increased MMP expression in healthy esophageal tissue as measured at the time of surgery. Since increased levels of MMPs are associated with severe postoperative complications including anastomotic leakage this finding necessitates further clinical research.
doi_str_mv 10.1245/s10434-009-0365-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67110774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1673783091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103</originalsourceid><addsrcrecordid>eNp1kVFLHDEUhYNYqrX9Ab5I8MG3qUlmJpl5lEWroFbEPoc7mTtultlkTTLS-fdm2QWh0KeEc7-ce8Ih5JSzn1xU9WXkrCqrgrG2YKWsC3ZAjnmdlUo2_DDfmWyKVsj6iHyLccUYVyWrv5Ij3gpRiYYfk_kRPfSr6R1cos_QW2-WuPZpiQE2M71zJiBEjPQBUrB_6QMmGEe_CT6hdXlCr0yy7zbN1Dp6izCm5UxfbIwTbpXr6DdLeM06XYAzGOgTJIsuxe_kywBjxB_784T8ubl-WdwW979_3S2u7gtTyjYVbSXqDkrV8hwYWdeqRjSqNQi9aHrEAVgjRJf_JXHoGR8EM6bpepASUHFWnpCLnW_O_DZhTHpto8FxBId-iloqzplSVQbP_wFXfgouZ9NCqLIWmckQ30Em-BgDDnoT7BrCrDnT21L0rhSdS9HbUvQ2wdneeOrW2H--2LeQAbEDYh65Vwyfm__v-gHmtpkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227352743</pqid></control><display><type>article</type><title>Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients</title><source>Springer Nature</source><creator>Rieff, E. A. ; Hendriks, T. ; Rutten, H. J. T. ; Nieuwenhuijzen, G. A. P. ; Gosens, M. J. E. M. ; van den Brule, A. J. C. ; Nienhuijs, S. W. ; de Hingh, I. H. J. T.</creator><creatorcontrib>Rieff, E. A. ; Hendriks, T. ; Rutten, H. J. T. ; Nieuwenhuijzen, G. A. P. ; Gosens, M. J. E. M. ; van den Brule, A. J. C. ; Nienhuijs, S. W. ; de Hingh, I. H. J. T.</creatorcontrib><description>Background Neoadjuvant radiochemotherapy (RCT) is thought to result in a favorable oncological outcome in esophageal cancer patients. Unfortunately, it also implies that adjacent healthy tissue is preoperatively exposed to the potential damaging influence of RCT. Here, the impact of preoperative RCT on matrix metalloproteinase (MMP) expression in healthy esophageal tissue aligned with the tumor at the time of surgery is examined. Patients and Methods 23 patients participating in a clinical trial were randomized to either the control ( n  = 12) or the neoadjuvant RCT group ( n  = 11). In the latter group, surgery was performed 5 weeks after the last course of RCT. Full-thickness biopsies were taken from healthy esophageal tissue at the proximal border of the resection specimen and more distally next to the tumor. MMP-2 and MMP-9 activity in the samples was assessed by quantitative gelatin zymography and immunohistochemistry. Results In the proximal segment, the activities of the MMP-9-dimer (135 kDa) and proMMP-9 (92 kDa) were significantly increased in the RCT group as compared with the control group: 28.5 versus 3.0 ( p  = 0.025) and 87.7 versus 13.0 ( p  = 0.015) arbitrary units for 135 kDa and 92 kDa, respectively. In the distal part, RCT resulted in a significant increase of proMMP-2 (72 kDa: 35.8 versus 17.8, p  = 0.005) and proMMP-9 (81.2 versus 23.3, p  = 0.03). Conclusion In esophageal cancer patients, neoadjuvant RCT results in increased MMP expression in healthy esophageal tissue as measured at the time of surgery. Since increased levels of MMPs are associated with severe postoperative complications including anastomotic leakage this finding necessitates further clinical research.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-009-0365-0</identifier><identifier>PMID: 19224281</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage ; Biopsy ; Carboplatin - administration &amp; dosage ; Chemotherapy, Adjuvant ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - therapy ; Esophagus - drug effects ; Esophagus - metabolism ; Esophagus - pathology ; Esophagus - radiation effects ; Female ; Gastrointestinal Oncology ; Humans ; Immunohistochemistry ; Male ; Matrix Metalloproteinase 2 - biosynthesis ; Matrix Metalloproteinase 9 - biosynthesis ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Neoadjuvant Therapy ; Oncology ; Paclitaxel - administration &amp; dosage ; Radiotherapy, Adjuvant ; Surgery ; Surgical Oncology</subject><ispartof>Annals of surgical oncology, 2009-05, Vol.16 (5), p.1384-1389</ispartof><rights>Society of Surgical Oncology 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103</citedby><cites>FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19224281$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rieff, E. A.</creatorcontrib><creatorcontrib>Hendriks, T.</creatorcontrib><creatorcontrib>Rutten, H. J. T.</creatorcontrib><creatorcontrib>Nieuwenhuijzen, G. A. P.</creatorcontrib><creatorcontrib>Gosens, M. J. E. M.</creatorcontrib><creatorcontrib>van den Brule, A. J. C.</creatorcontrib><creatorcontrib>Nienhuijs, S. W.</creatorcontrib><creatorcontrib>de Hingh, I. H. J. T.</creatorcontrib><title>Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background Neoadjuvant radiochemotherapy (RCT) is thought to result in a favorable oncological outcome in esophageal cancer patients. Unfortunately, it also implies that adjacent healthy tissue is preoperatively exposed to the potential damaging influence of RCT. Here, the impact of preoperative RCT on matrix metalloproteinase (MMP) expression in healthy esophageal tissue aligned with the tumor at the time of surgery is examined. Patients and Methods 23 patients participating in a clinical trial were randomized to either the control ( n  = 12) or the neoadjuvant RCT group ( n  = 11). In the latter group, surgery was performed 5 weeks after the last course of RCT. Full-thickness biopsies were taken from healthy esophageal tissue at the proximal border of the resection specimen and more distally next to the tumor. MMP-2 and MMP-9 activity in the samples was assessed by quantitative gelatin zymography and immunohistochemistry. Results In the proximal segment, the activities of the MMP-9-dimer (135 kDa) and proMMP-9 (92 kDa) were significantly increased in the RCT group as compared with the control group: 28.5 versus 3.0 ( p  = 0.025) and 87.7 versus 13.0 ( p  = 0.015) arbitrary units for 135 kDa and 92 kDa, respectively. In the distal part, RCT resulted in a significant increase of proMMP-2 (72 kDa: 35.8 versus 17.8, p  = 0.005) and proMMP-9 (81.2 versus 23.3, p  = 0.03). Conclusion In esophageal cancer patients, neoadjuvant RCT results in increased MMP expression in healthy esophageal tissue as measured at the time of surgery. Since increased levels of MMPs are associated with severe postoperative complications including anastomotic leakage this finding necessitates further clinical research.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage</subject><subject>Biopsy</subject><subject>Carboplatin - administration &amp; dosage</subject><subject>Chemotherapy, Adjuvant</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagus - drug effects</subject><subject>Esophagus - metabolism</subject><subject>Esophagus - pathology</subject><subject>Esophagus - radiation effects</subject><subject>Female</subject><subject>Gastrointestinal Oncology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Matrix Metalloproteinase 2 - biosynthesis</subject><subject>Matrix Metalloproteinase 9 - biosynthesis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Oncology</subject><subject>Paclitaxel - administration &amp; dosage</subject><subject>Radiotherapy, Adjuvant</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kVFLHDEUhYNYqrX9Ab5I8MG3qUlmJpl5lEWroFbEPoc7mTtultlkTTLS-fdm2QWh0KeEc7-ce8Ih5JSzn1xU9WXkrCqrgrG2YKWsC3ZAjnmdlUo2_DDfmWyKVsj6iHyLccUYVyWrv5Ij3gpRiYYfk_kRPfSr6R1cos_QW2-WuPZpiQE2M71zJiBEjPQBUrB_6QMmGEe_CT6hdXlCr0yy7zbN1Dp6izCm5UxfbIwTbpXr6DdLeM06XYAzGOgTJIsuxe_kywBjxB_784T8ubl-WdwW979_3S2u7gtTyjYVbSXqDkrV8hwYWdeqRjSqNQi9aHrEAVgjRJf_JXHoGR8EM6bpepASUHFWnpCLnW_O_DZhTHpto8FxBId-iloqzplSVQbP_wFXfgouZ9NCqLIWmckQ30Em-BgDDnoT7BrCrDnT21L0rhSdS9HbUvQ2wdneeOrW2H--2LeQAbEDYh65Vwyfm__v-gHmtpkg</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Rieff, E. A.</creator><creator>Hendriks, T.</creator><creator>Rutten, H. J. T.</creator><creator>Nieuwenhuijzen, G. A. P.</creator><creator>Gosens, M. J. E. M.</creator><creator>van den Brule, A. J. C.</creator><creator>Nienhuijs, S. W.</creator><creator>de Hingh, I. H. J. T.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20090501</creationdate><title>Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients</title><author>Rieff, E. A. ; Hendriks, T. ; Rutten, H. J. T. ; Nieuwenhuijzen, G. A. P. ; Gosens, M. J. E. M. ; van den Brule, A. J. C. ; Nienhuijs, S. W. ; de Hingh, I. H. J. T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage</topic><topic>Biopsy</topic><topic>Carboplatin - administration &amp; dosage</topic><topic>Chemotherapy, Adjuvant</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagus - drug effects</topic><topic>Esophagus - metabolism</topic><topic>Esophagus - pathology</topic><topic>Esophagus - radiation effects</topic><topic>Female</topic><topic>Gastrointestinal Oncology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Matrix Metalloproteinase 2 - biosynthesis</topic><topic>Matrix Metalloproteinase 9 - biosynthesis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Oncology</topic><topic>Paclitaxel - administration &amp; dosage</topic><topic>Radiotherapy, Adjuvant</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rieff, E. A.</creatorcontrib><creatorcontrib>Hendriks, T.</creatorcontrib><creatorcontrib>Rutten, H. J. T.</creatorcontrib><creatorcontrib>Nieuwenhuijzen, G. A. P.</creatorcontrib><creatorcontrib>Gosens, M. J. E. M.</creatorcontrib><creatorcontrib>van den Brule, A. J. C.</creatorcontrib><creatorcontrib>Nienhuijs, S. W.</creatorcontrib><creatorcontrib>de Hingh, I. H. J. T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rieff, E. A.</au><au>Hendriks, T.</au><au>Rutten, H. J. T.</au><au>Nieuwenhuijzen, G. A. P.</au><au>Gosens, M. J. E. M.</au><au>van den Brule, A. J. C.</au><au>Nienhuijs, S. W.</au><au>de Hingh, I. H. J. T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>16</volume><issue>5</issue><spage>1384</spage><epage>1389</epage><pages>1384-1389</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background Neoadjuvant radiochemotherapy (RCT) is thought to result in a favorable oncological outcome in esophageal cancer patients. Unfortunately, it also implies that adjacent healthy tissue is preoperatively exposed to the potential damaging influence of RCT. Here, the impact of preoperative RCT on matrix metalloproteinase (MMP) expression in healthy esophageal tissue aligned with the tumor at the time of surgery is examined. Patients and Methods 23 patients participating in a clinical trial were randomized to either the control ( n  = 12) or the neoadjuvant RCT group ( n  = 11). In the latter group, surgery was performed 5 weeks after the last course of RCT. Full-thickness biopsies were taken from healthy esophageal tissue at the proximal border of the resection specimen and more distally next to the tumor. MMP-2 and MMP-9 activity in the samples was assessed by quantitative gelatin zymography and immunohistochemistry. Results In the proximal segment, the activities of the MMP-9-dimer (135 kDa) and proMMP-9 (92 kDa) were significantly increased in the RCT group as compared with the control group: 28.5 versus 3.0 ( p  = 0.025) and 87.7 versus 13.0 ( p  = 0.015) arbitrary units for 135 kDa and 92 kDa, respectively. In the distal part, RCT resulted in a significant increase of proMMP-2 (72 kDa: 35.8 versus 17.8, p  = 0.005) and proMMP-9 (81.2 versus 23.3, p  = 0.03). Conclusion In esophageal cancer patients, neoadjuvant RCT results in increased MMP expression in healthy esophageal tissue as measured at the time of surgery. Since increased levels of MMPs are associated with severe postoperative complications including anastomotic leakage this finding necessitates further clinical research.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>19224281</pmid><doi>10.1245/s10434-009-0365-0</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1068-9265
ispartof Annals of surgical oncology, 2009-05, Vol.16 (5), p.1384-1389
issn 1068-9265
1534-4681
language eng
recordid cdi_proquest_miscellaneous_67110774
source Springer Nature
subjects Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biopsy
Carboplatin - administration & dosage
Chemotherapy, Adjuvant
Esophageal Neoplasms - metabolism
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophagus - drug effects
Esophagus - metabolism
Esophagus - pathology
Esophagus - radiation effects
Female
Gastrointestinal Oncology
Humans
Immunohistochemistry
Male
Matrix Metalloproteinase 2 - biosynthesis
Matrix Metalloproteinase 9 - biosynthesis
Medicine
Medicine & Public Health
Middle Aged
Neoadjuvant Therapy
Oncology
Paclitaxel - administration & dosage
Radiotherapy, Adjuvant
Surgery
Surgical Oncology
title Neoadjuvant Radiochemotherapy Increases Matrix Metalloproteinase Activity in Healthy Tissue in Esophageal Cancer Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T18%3A59%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20Radiochemotherapy%20Increases%20Matrix%20Metalloproteinase%20Activity%20in%20Healthy%20Tissue%20in%20Esophageal%20Cancer%20Patients&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Rieff,%20E.%20A.&rft.date=2009-05-01&rft.volume=16&rft.issue=5&rft.spage=1384&rft.epage=1389&rft.pages=1384-1389&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-009-0365-0&rft_dat=%3Cproquest_cross%3E1673783091%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-9425ba3791428e0b9782879cead28deefa0822b3056efd01f20cc8bda66ae7103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=227352743&rft_id=info:pmid/19224281&rfr_iscdi=true